Biphenyl derivative compound and use thereof

Patent metadata

Field	Value
Publication number	US-12043594-B2
Application number	US-201917059762-A
Country	US
Kind code	B2
Filing date	May 30, 2019
Priority date	May 30, 2018
Publication date	Jul 23, 2024
Grant date	Jul 23, 2024

Abstract

The present disclosure provides a novel biphenyl derivative compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to the present disclosure may induce cancer cell death by damaging mitochondria and inducing ATP depletion in cells which are in a nutrient-starved state such as a glucose-starved state, which is the normal environment of cancer cells. In addition, it is an Nm23-H1/NDPK activity-increasing substance that may suppress cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.

First claim

The invention claimed is:

1. A biphenyl derivative compound of Formula 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof:

wherein
L is —(CH 2 )—, —(C(═O))— or —(CHOH)—;
each of R 1 , R 2 , R 3 and R 4 is independently hydroxy or methoxy.

2. The biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to claim 1 , wherein each of R 1 , R 2 , R 3 and R 4 is methoxy.

3. The biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to claim 1 , wherein L is —(CH 2 )— or —(CHOH)—.

4. The biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound of Formula 1 is selected from among the following compounds:

5. A pharmaceutical composition for treating cancer, the pharmaceutical composition containing, as an active ingredient, the biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to claim 1 , wherein the cancer is breast cancer.

6. The pharmaceutical composition of claim 5 , further containing an anticancer agent that exhibits a synergistic effect with the biphenyl derivative compound, the optical isomer thereof or the pharmaceutically acceptable salt thereof.

7. The pharmaceutical composition of claim 6 , wherein the anticancer agent is an anticancer agent selected from the group consisting of cisplatin, carboplatin, oxalliplatin, paclitaxel, docetaxel, vincristine, doxorubicin, daunorubicin, bleomycin, prednisone, methotrexate (MTX), 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and combinations thereof.

8. A method for treating cancer, the method comprising a step of administering the pharmaceutical composition according to claim 5 to a subject that is or has developed cancer, wherein the cancer is breast cancer.

9. A composition for suppressing cancer metastasis, the composition containing, as an active ingredient, the biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to claim 1 , wherein the cancer is breast cancer.

10. A method for suppressing cancer metastasis, the method comprising a step of administering the composition according to claim 9 to a subject that is at risk of cancer metastasis or has metastasized cancer, wherein the cancer is breast cancer.

11. A food composition for alleviating cancer, the food composition containing, as an active ingredient, the biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to claim 1 , wherein the cancer is breast cancer.

12. The method of claim 8 , further comprising a step of administering to the subject an anticancer agent selected from the group consisting of cisplatin, carboplatin, oxalliplatin, paclitaxel, docetaxel, vincristine, doxorubicin, daunorubicin, bleomycin, prednisone, methotrexate (MTX), 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and combinations thereof.

Assignees

• Ewha University—Industry Collaboration Found

Inventors

• Lee Kong Joo
• Lee Hee-Yoon
• Lee Je Jin
• Lee Hongsoo
• Seo Ji-Wan
• Kim Hwang Suk
• Kim Bo-Kyung
• Shin Ji Soo

Classifications

• C07C49/175

  containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K31/12

  Ketones · CPC title

• A61K31/09

  having two or more such linkages · CPC title

• A61K9/0056

  Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals · CPC title